Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Nephrotic Syndrome

Rituximab Versus Mycophenolate Mofetil in Children With Steriod-dependent Nephrotic Syndrome: A Single-center, Randomized Controlled Trial

The goal of this clinical trial is to evaluate the efficacy and safety of rituximab(RTX) and mycophenolate mofetile(MMF) in the treatment of children with low-dose steroid-dependent nephrotic syndrome(SDNS).

Study Overview

• Status: Recruiting
• Conditions: Nephrotic Syndrome in Children
• Intervention / Treatment: Drug: Rituximab; Drug: Mycophenolate Mofetil

Detailed Description

Idiopathic nephrotic syndrome（INS） is the most common glomerular disease in childhood. Currently, steroids are the primary treatment, but there are significant steroid-related toxicity, such as growth disorders, behavior changes, obesity, Cushing's syndrome, eye disease, osteoporosis, etc.

Both MMF and RTX have been shown to be effective in the treatment of SDNS, and there is a lack of prospective controlled studies to explore the optimal treatment regimen for low-dose SDNS. Therefore, the investigators will conduct a single-center, randomized controlled trial to evaluate the efficacy and safety of twice-daily rituximab(RTX) versus mycophenolate mofetil(MMF) in the treatment of children with low-dose steroid-dependent nephrotic syndrome(SDNS).

After the start of the study, all participants will be screened consecutively and eligible participants will be included in the study. Bias of potential influencing factors will be addressed by inclusion as covariates in the statistical analysis. Independent clinical site monitoring to ensure the safety and integrity of clinical data while patients adhere to the study protocol will focus on source data documentation, strict adherence to data correctness and study procedures, such as randomization and treatment.

• Study Type: Interventional
• Enrollment (Estimated): 46
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Yang Haiping, Doctor; Phone Number: 8618983703661; Email: oyhp@hospital.cqmu.edu.cn

Study Locations

• China
  • Chongqing
    • Chongqing, Chongqing, China, 400014
      • Recruiting
      • Children's hospital of Chongqing Medical University
      • Contact: Li Qiu, Doctor; Phone Number: 8613708353809; Email: liqiu809@hospital.cqmu.edu.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Children with a definite diagnosis of SDNS are included in the study during relapse treatment.
• Age 3-16 years.
• Steroid dependent dose≤0.3mg/kg/day.
• Cumulative steroid use for ≥6 months.
• Ability to swallow tablet.
• Guardians understand the characteristics and personal consequences of clinical trial.
• Guardians willing to give informed written consent.

Exclusion Criteria:

• Diagnosis of secondary NS, such as secondary to lupus nephritis, hepatitis B-related nephritis, purpura nephritis, etc.
• Anti-neutrophil cytoplasmic antibodies(ANCA) positive or complement C3 level decreased.
• Diagnosis of hereditary nephrotic syndrome.
• Full dose of prednisone (2mg/kg/day, maximum 60mg) are used for 14 days after relapse and urine protein don't turn negative.
• Estimated glomerular filtration rate (eGFR) <90mL/min per 1.73m^2 at study entry.
• Those who with a known allergy to Mycophenolate Mofetil and their excipients or to Rituximab and its excipients.
• Those who refuse to participate in the trial.
• Those who participate other clinical trials.
• Those who with positive HBV serological markers (HBsAg or/and HBeAg or/and HBcAb), HCV positive patients or patients with abnormal liver function (ALT,AST,or bilirubin>2 or more times the upper limit of the normal range and persistently elevated for 2 weeks).
• Severe leukopenia (white blood cells<3.0×10^9), severe anemia (hemoglobin<90g/l), and thrombocytopenia (platelets<100×10^9) at study entry.
• History of pancreatitis or definite gastrointestinal ulcers and/or gastrointestinal bleeding within 6 months.
• Those who with congenital or acquired immune deficiency, or with active tuberculosis, active CMV and other infections.
• Those who with other serious physical or mental illnesses.
• History of malignant tumor within 5 years.
• Those who with congenital heart disease, arrhythmia, heart failure and other serious cardiovascular diseases.
• Those who with serious infections requiring intravenous antibiotics.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Rituximab; 2 doses of rituximab 375 mg/m^2 (Maximum 500mg/day)at 6 months intervals	Drug: Rituximab; 2 doses of rituximab 375 mg/m^2(maximum 500mg/day) at 6 months intervals. Half an hour before rituximab infusion: oral acetaminophen 15mg/kg, oral or intramuscular antihistamine, methylprednisolone 2mg/kg IV. Trimethoprim-sulfamethoxazole should be administered orally from the initiation of rituximab therapy until peripheral-blood B cell recovery to prevent pneumocystis infection.; Other Names: Rituximab Injection
Active Comparator: Mycophenolate Mofetil; MMF 20~30mg/kg/day，BID	Drug: Mycophenolate Mofetil; Mycophenolate Mofetil 20-30 mg/kg/day BID,then adjust the dosage of drugs(maximum 2g/day) to maintian the concentration for MPA-AUC is 30-50μg.h/ml. Total duration:1year. Steroids dose:1.5mg/kg(maximum 40mg) qod for 2 weeks and gradually taper by 0.3 mg/kg every 2 weeks; Other Names: Mycophenolate Mofetil Dispersible tablets

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
12-month relapse-free survival rate	The rate of no relapse within 12 months.	12 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
6-month relapse-free survival	Relapse-free survival within 6 months.	6 months
6-month relapse-free survival rate	The rate of no relapse within 6 months.	6 months
12-month relapse-free survival	Relapse-free survival within 12 months.	12 months
Proportion of frequent relapses	The proportion of frequent relapses.Frequent relapsing NS:≥2 relapses per 6 months within 6 months of disease onset or ≥4 relapses per 12 months in any subsequent 12-month period.	Months 6,12
Cumulative steroid dosage	The total dosage of steroid from the beginning to the end of the trial.	12 months
Number of relapses within 0-12,0-6, and 7-12 months	Number of relapses within 0-6 months,7-12 months, and total within 0-12 months.	12 months
Time of first relapse	The first time to relapse after patients taking part in this study.	12 months
Proportion of participants who discontinued steroids	Proportion of participants who discontinued steroids at 12 months	12 months
Height standard deviation score(SDS)	SDS of height at 6 and 12 months, absolute and relative changes in SDS from baseline to 12 months.	months 0,6,12
Body mass index(BMI)	Weight and height will be combined to report BMI in kg/m^2. BMI at 6 and 12 months, absolute and relative changes in BMI from baseline to 12 months.	Months 0,6,12
Quality of life score	The researchers assess the quality of life of the participants useing Pediatric Quality of Life Inventory (PedsQL).	Baseline to 12 months
Cost of treatment	The researchers calculate their cost during the study.	12 months
Adverse event	It is a binary variable(1/0).The varibale would be setted as "1" if any adverse events occours including obesity, hypertrichosis, psychological disorders,glaucoma,neutropenia,hypogammaglobulinemia, rituximab-related lung injury, fatal hepatitis reactivation, multifocal leukoencephalopathy,severe diarrhea, severe infection. Adverse events graded according to Common Terminology Criteria For Adverse Events (CTCAE v4.0）	12 months

Collaborators and Investigators

• Sponsor: Children's Hospital of Chongqing Medical University

Study record dates

Study Major Dates

• Study Start (Actual): January 29, 2023
• Primary Completion (Estimated): July 1, 2026
• Study Completion (Estimated): July 1, 2026

Study Registration Dates

• First Submitted: April 8, 2023
• First Submitted That Met QC Criteria: May 3, 2023
• First Posted (Actual): May 6, 2023

Study Record Updates

• Last Update Posted (Actual): April 19, 2024
• Last Update Submitted That Met QC Criteria: April 18, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Keywords: Rituximab; Mycophenolate Mofetil; Nephrotic Syndrome
• Additional Relevant MeSH Terms: Pathologic Processes; Kidney Diseases; Urologic Diseases; Disease; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Syndrome; Nephrotic Syndrome; Nephrosis; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Enzyme Inhibitors; Antirheumatic Agents; Antineoplastic Agents; Immunologic Factors; Antineoplastic Agents, Immunological; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antitubercular Agents; Antibiotics, Antitubercular; Rituximab; Mycophenolic Acid
• Other Study ID Numbers: HYang

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No